Stockwinners Market Radar for May 09, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:03 EDT Cathie Wood's ARK Investment bought 242K shares of Prime Medicine today

20:02 EDT Cathie Wood's ARK Investment bought 125K shares of Joby Aviation today

19:28 EDT Select Medical chairman sells $4.94M in common stock - In a regulatory filing, Select Medical disclosed that its Chairman Robert Ortenzio sold 166K shares of common stock on May 8th in a total transaction size of $4.94M

19:11 EDT Azek CEO Singh sells 40,000 class A common shares - In a regulatory filing, Azek president and CEO Jesse Singh disclosed the sale of 40,000 class A common shares of the company on May 9 at a price of $25.34 per share.

18:02 EDT Theravance Biopharma: FDA grants ODD status to ampreloxetine - Theravance Biopharma announced that the U.S. FDA has granted Orphan Drug Designation status to ampreloxetine for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy. MSA is a rare neurodegenerative disorder in which patients suffer autonomic dysfunction affecting movement, balance, heart rate and blood pressure. Many patients with MSA suffer from the debilitating symptoms of nOH including dizziness, disrupted vision, muscle weakness, head and neck discomfort, and fatigue, which adversely affect quality of life.

17:49 EDT Joann CEO Wade Miquelon retires - Joann announced the retirement of Wade Miquelon as president and CEO effective May 8. Chris DiTullio, executive VP and chief customer officer, and Scott Sekella, executive VP and CFO, have been appointed to lead the interim office of the CEO, and the board has commenced a search to identify a permanent replacement.

17:45 EDT Carlyle Secured Lending reports Q1 net investment income 50c - Reports Q1 NAV per common share increased by 0.6% to $17.09 from $16.99 as of December 31, 2022. Aren LeeKong, CSL's CEO said, "Our Q1 results reflected the continued earnings strength and credit performance of our portfolio. The terms and pricing available in today's loan market remain lender friendly and represent a particularly attractive vintage for putting capital to work. This backdrop allows us to be highly selective and committed to disciplined credit underwriting combined with prudent risk management."

17:45 EDT Amerant Bancorp names Sharymar Calderon CFO - Amerant Bancorp announced that Sharymar Calderon will become executive VP, CFO for the company and the bank effective June 1. Calderon has served as senior VP, head of internal audit at Amerant since June 2021, where she has led the implementation and monitoring of the company's audit plan and risk assessments, including coordination with external auditors and the integration of SOX audits.

17:39 EDT Artesian Resources increases quarterly dividend 2% to 28.4c per share - Artesian Resources announced that its board of directors approved a 2% increase in the quarterly dividend per share on the company's Class A and Class B common stock, which raises the annualized dividend rate to $1.14 per share. The quarterly dividend rate of 28.4c per share is payable May 26 to shareholders of record at the close of business on May 19.

17:24 EDT U.S. Bancorp exec buys $497.5K in common stock - In a regulatory filing, U.S. Bancorp disclosed that its Vice Chair James Kelligrew bought 16.3K shares of common stock on May 8th in a total transaction size of $497.5K.

17:12 EDT Nutanix announces new capabilities in Nutanix Cloud Platform - Nutanix announced new capabilities in the Nutanix Cloud Platform to enable customers to integrate data management of containerized and virtualized applications on-premises, on public cloud, and at the edge. This includes comprehensive data services for Kubernetes applications as well as cross-cloud data mobility. According to IDC, by 2025 there will be 750 million new logical applications, more than the past 40 years of computing, all generating large amounts of data across clouds. This means it will be paramount for organizations to integrate management of data for both containerized and virtualized applications as well as across multiple environments. "According to the Enterprise Cloud Index, nearly all enterprises have started using Kubernetes for their containerized applications. Now IT teams need to find a way to both enable their developers with self-service data services, while also ensuring governance and security policies are applied uniformly," said Thomas Cornely, SVP, Product Management at Nutanix. "With Nutanix Data Services for Kubernetes, the Nutanix Cloud Platform will extend storage provisioning, snapshots, and disaster recovery operations to Kubernetes applications to help accelerate containerized application development in the enterprise."

17:11 EDT Cutera announces agreements with Pura Vida, RTW - Cutera announced that it has entered into cooperation agreements with two of its largest stockholders, Pura Vida Investments, LLC and RTW Investments, LP, which collectively own more than 15% of the Company's outstanding shares. Pursuant to the Agreements, the Company will appoint Kevin J. Cameron, Taylor C. Harris, Nicholas S. Lewin and Keith J. Sullivan to the Board of Directors following the Special Meeting of Stockholders to be held on June 9, 2023. Mr. Harris will also serve as a special advisor and consultant to the Company. The New Independent Directors and three incumbent directors, Janet D. Widmann, Sheila A. Hopkins, and Juliane T. Park, will be nominated for election to the Board at the Company's 2023 Annual Meeting of Stockholders. The Company anticipates that its new permanent CEO, when identified and hired, will also join the Board. In connection with the agreement, Pura Vida and RTW have agreed to vote against the removal of directors at the upcoming Special Meeting and to support the Board Slate at the Annual Meeting. Janet D. Widmann, Chair of the Cutera Board of Directors, said, "As Cutera evolves, ensuring that our Board has the skills and expertise to oversee the strategy and execution of the business is paramount. We appreciate the time and input of our stockholders, including Pura Vida and RTW, as we reconstitute the Board to ensure diverse perspectives and relevant experience are present on the Board. We look forward to welcoming the new directors to our Board."

17:08 EDT Ovintiv sees FY23 total production 520-545 MBOE/d

17:06 EDT LuxUrban Hotels signs master lease pacts to operate hotels in NYC, LA - LuxUrban Hotels announced that it has signed a 25-year Master Lease Agreement (MLA), inclusive of two five-year options, to operate the Condor Hotel in Williamsburg, Brooklyn ("Condor Hotel"). The Company also signed a 15-year MLA, inclusive of one five-year option, to operate the Trinity Hotel ("Trinity") in Los Angeles, California. The Company expects to commence operations at the Condor Hotel and Trinity on or about July 1, 2023. In total, these new properties will add 214 units to the Company's growing portfolio of short-stay hotel rooms. The Company also announced that effective May 1, 2023 it commenced operations at 101 Bogart Street, a 65-unit, mix-used, seven-story property in East Williamsburg-Bushwick, Brooklyn. 101 Bogart is in a growing, industrial / art-infused community of startups, entrepreneurs, and freelancers that includes a 170,000-square-foot state-of-the-art Netflix production facility. "New York City is expected to welcome more than 60 million visitors in 2023 and approach pre-pandemic levels of tourism. With the opening of 101 Bogart we are currently operating six hotels in New York City and the expected addition of the Condor will add greater density and diversity to our largest market at an exciting time of growth and recovery," said Brian Ferdinand, Chairman and CEO of LuxUrban Hotels. "Downtown Los Angeles offers a wide array of cultural, entertainment, and business activities and the region's improving hospitality market reflects the abundance of opportunities that this bustling commercial and residential hub provides."

17:04 EDT Rocket Lab completes custom-built photon spacecraft for Varda Space - Rocket Lab USA announced it has completed and shipped a custom Photon spacecraft developed for Varda Space Industries, a leading in-space manufacturing and hypersonic re-entry logistics company. The Rocket Lab-designed and built Photon spacecraft will provide power, communications, propulsion, and attitude control to Varda's 120kg capsule that will produce pharmaceutical products in microgravity and return them to Earth. In addition to providing support during the in-space manufacturing phase of Varda's mission, the Photon will place Varda's hypersonic re-entry capsule on a return trajectory to Earth. "Opening access to space is about much more than launch for Rocket Lab. It's about making it easier to put the ideas of tomorrow in orbit today, enabling innovation, rapid iteration, and new capabilities that will improve lives back on Earth. This is exactly what the team at Varda is doing by producing novel pharmaceuticals in orbit and we're immensely proud to make that possible with our Photon spacecraft," said Rocket Lab founder and CEO, Peter Beck. "Space Systems is a rapidly growing part of Rocket Lab's business, and we're delighted to deliver another spacecraft that leverages our vertical integration strategy for high-quality and cost-effective satellite solutions on rapid timelines."

17:02 EDT Adicet Bio expects cash to fund operations into first half of 2025 - Cash Position: Cash and cash equivalents were $231.6 million as of March 31, 2023, compared to $277.9 million during the same period in 2022. The Company expects that current cash and cash equivalents as of March 31, 2023, will be sufficient to fund its operating expenses into the first half of 2025.

17:00 EDT Topgolf Callaway falls 8% to $19.90 after cutting FY23 EPS outlook

16:48 EDT AerSale provides update on AerAware - AerSale said: "The FAA approval process is lengthy and exhaustive to ensure public safety, which is underscored by the excellent safety record of US commercial aviation. Through this process we have continually improved the system, resulting in safety and quality advancements that lead us to believe we have a system superior to anything available on the commercial market today. Further, given the advanced technology we are bringing to the market, combined with the substantial investment of time and resources to obtain an STC, we believe we will be in an excellent position to become the leader in the category. To that end, after demonstrating to the FAA how the system worked in low visibility conditions, we received positive feedback on the low visibility function of our enhanced flight vision system. We are excited to be near completion considering all the progress we have made with the FAA and the interest we have received from multiple potential customers."

16:42 EDT Clean Energy sbacks FY23 adjusted EBITDA view of $50M-$60M vs. $50M in FY22

16:36 EDT Steakholder Foods CFO Eitan Noah to step down - Steakholder Foods announced that Moran Attar, CPA, is joining the team as Vice-President of Finance following the decision of the company's CFO, Eitan Noah, to step down from his position. Noah stated that his resignation was for personal reasons, and not due to any dispute with the company.

16:34 EDT Vizio sees Q2 adjusted EBITDA $6M-$11M - Sees Q2 Platform+ Net Revenue $133M - $137M and Platform+ Gross Profit $78M - $83M

16:31 EDT Invesco reports preliminary AUM $1.48T as of April 30 - An increase of 0.1% versus previous month-end. The firm experienced net long-term outflows of $2.2 billion in the month. Non-management fee earning net outflows were $2.1 billion and money market net inflows were $1.4 billion. AUM was positively impacted by favorable market returns which increased AUM by $5 billion. FX decreased AUM by $0.4 billion. Preliminary average total AUM for the quarter through April 30 were $1.469T, and preliminary average active AUM for the quarter through April 30 were $992.0 billion.

16:31 EDT Compass Minerals acquires outstanding 55% interest in Fortress North America - Compass Minerals announced that it has acquired the outstanding 55% interest in Fortress North America (Fortress), a next-generation fire retardant company, bringing the company's ownership stake to 100%. Building upon a previous 45% minority ownership stake that Compass Minerals has held in Fortress since January 2022, the transaction provides Compass Minerals full ownership of all Fortress assets, contracts and intellectual property. "The value creation possible through the full integration of Fortress' patented portfolio of next-gen fire retardant formulations with our extensive logistics and production capabilities made this acquisition a priority for our company," said Kevin S. Crutchfield, president and CEO. "With the recent milestones attained by Fortress, our confidence in its earnings potential is bolstered as we gain a share of the next-gen fire retardant market, a counter-seasonal opportunity and sizeable addressable market that is now open to us. We are pleased to welcome the Fortress team into the Compass Minerals family." The leadership team at Fortress, including CEO Robert Burnham, will continue to lead and develop the business.

16:29 EDT AllianceBernstein reports preliminary AUM $676B as of April 30 - Unchanged versus March month-end. April AUM reflected slight market gains, offset by firm-wide net outflows. By channel, outflows were concentrated within Institutions reflecting previously announced redemptions of certain low-fee Custom Target Date and Fixed Income mandates. Private Wealth posted negative net flows while Retail net flows were flat.

16:23 EDT Rivian Automotive backs annual guidance for 50,000 units produce - Rivian said: "We remain focused on ramping production and implementing core technologies designed to drive cost down and improve the customer offering. Based on our latest understanding of the supply chain environment, we reaffirm the annual guidance provided during our fourth quarter and fiscal year 2022 earnings call of 50,000 total units of production, $(4,300) million in adjusted EBITDA, and $2,000 million in capital expenditures. We continue to believe the supply chain will continue to be the main limiting factor of our Normal facility output. Our team continues to work on the introduction of new engineering design changes and key technologies which will take effect during the second half of 2023 to help mitigate anticipated supply chain constraints."

16:13 EDT Performant Financial names Simeon Kohl as CEO, board member - Performant Financial Corporation announced that effective May 5th, Simeon Kohl has been promoted to the position of CEO and a member of Performant's Board of Directors. Lisa Im, the company's previous CEO, will continue in her role as Board Chair. "As the transition to a pure-play healthcare company is now complete, it is the right time for me to hand over the reins to Simeon Kohl, who will continue to execute his exciting vision for the growth of Performant Healthcare Solutions," said Im. "From the time I first met Simeon, it was very clear to me that he was a visionary with a bright future ahead of him. Together with the leadership team he has built, Sim has achieved remarkable results and demonstrated consistent growth of our healthcare business." Additionally, the Board has promoted Rohit Ramchandani to the role of Chief Finance Officer. For the past two years, Mr. Ramchandani has been serving as the company's Senior Vice President of Finance and Strategy.

16:11 EDT Compass sees FY23 adjusted operating expense $850M-$950M - Expects to be free cash flow positive for FY23.

16:10 EDT Airbnb sees Q2 adjusted EBITDA 'similar to' Q2 last year on nominal basis - Airbnb said: "In Q2 2023, we expect Adjusted EBITDA to be similar to Adjusted EBITDA in Q2 2022 on a nominal basis, but lower on a margin basis. This anticipated year-over-year decline in Adjusted EBITDA margin is primarily driven by changes in the expected timing of our marketing spend relative to the prior year. Compared to Q2 2022, we expect that Sales and Marketing expense in Q2 2023 will be approximately 400 basis points higher as a percent of revenue as we deploy marketing earlier in the year than last year. We continue to anticipate a full year Adjusted EBITDA margin that is broadly in-line with full-year 2022."

16:05 EDT Evolus reports expansion into U.S. dermal filler market with Evolysse - Evolus announced it has entered into a definitive agreement to be the exclusive U.S. distributor of a line of five dermal fillers currently in late-stage development. The addition of a filler line expands the company's total addressable U.S. market by 70% by adding a $1.6 billion U.S. filler market opportunity to the existing $2.3 billion aesthetic neurotoxin market, with both markets expected to nearly double by 2028, the company said in a statement. As a result of this product expansion, the company has raised its 2028 revenue outlook by $200 million to $700 million. "Today's announcement represents a material step in achieving our goal of transforming Evolus into a multi-product aesthetics company," said David Moatazedi, Evolus' President and Chief Executive Officer. "We are excited to expand our portfolio with Evolysse(TM), a highly competitive filler line that complements our fast-growing aesthetic neurotoxin, Jeuveau(R). Injectables are the cornerstone of aesthetics with neurotoxins and dermal fillers as the top two aesthetic procedures in the U.S. Our customer-centric approach, existing digital infrastructure and distribution platform will power the launch of this innovative filler technology into the hands of our customers and their patients."

16:02 EDT Take-Two's Private Division announces partnership with Game Freak - Private Division, a publishign label of Take-Two, announced a partnership to publish a new title from Game Freak. Founded in 1989, the Japanese development company has created dozens of hit games, including more than 30 entries in the Pokemon franchise, which is widely recognized as one of the best-selling game series of all time. Private Division will publish a brand-new action-adventure IP from Game Freak, codenamed Project Bloom. To celebrate this announcement, Private Division and Game Freak have unveiled the first piece of concept art for the game. "We're thrilled to have the opportunity to create new IP that is bold and tonally different from our prior work," said Kota Furushima, Director at Game Freak. "From the beginning, Private Division was the publisher we wanted to work with on our new game. Their track record and global expertise give us all the confidence to create a sweeping new action-adventure game that we can't wait to share more about in the future." Project Bloom is in early development and does not yet have an announced release date. It is expected to launch during Take-Two's Fiscal Year 2026. Private Division and Game Freak look forward to sharing more details about this game in the future.

15:33 EDT IBM unveils new AI and data platform Watsonx to enhance impact of AI - IBM at its annual Think conference, announced IBM watsonx, a new AI and data platform to be released that will enable enterprises to scale and accelerate the impact of the most advanced AI with trusted data. Enterprises turning to AI today need access to a full technology stack that enables them to train, tune and deploy AI models, including foundation models and machine learning capabilities, across their organization with trusted data, speed, and governance - all in one place and to run across any cloud environment. Also at Think, IBM is announcing further planned advancements, including a GPU-as-a-service infrastructure offering designed to support AI-intensive workloads, an AI-powered dashboard to measure, track, manage, and help report on cloud carbon emissions, and a new practice for watsonx and generative AI from IBM Consulting that will support client deployment of AI. With watsonx, IBM is offering an AI development studio with access to IBM-curated and trained foundation models and open-source models, access to a data store to enable the gathering and cleansing of training and tuning data, and a toolkit for governance of AI into the hands of businesses that will provide a seamless end-to-end AI workflow that will make AI easier to adapt and scale...Clients will have access to the toolset, technology, infrastructure, and consulting expertise to build their own - or fine-tune and adapt available AI models - on their own data and deploy them at scale in a more trustworthy and open environment to drive business success. Competitive differentiation and unique business value will be able to be increasingly derived from how adaptable an AI model can be to an enterprise's unique data and domain knowledge.

15:22 EDT State Department approves Oshkosh FMS sale to Slovakia for JLTVs - The State Department has made a determination approving a possible Foreign Military Sale to the Government of Slovakia of M1278A1/A2 Heavy Gun Carriers Joint Light Tactical Vehicles, or JLTVs, and related equipment and services for an estimated cost of $250M. The Defense Security Cooperation Agency delivered the required certification notifying Congress of this possible sale. The Government of Slovakia has requested to buy 192 M1278A1/A2 Heavy Gun Carriers Joint Light Tactical Vehicles (JLTVs) as well as M153 Common Remote Weapons Stations, or CROWS, with Display and Control Panels, or DCP; M2 Quick Change Barrels, or QCB, .50 caliber machine guns; MK19 40mm grenade launchers; M2A1 machine guns; M4A1 Joint Chemical Agent Detectors; AN/VAS-5B2 Driver's Vision Enhancers; JLTV kits; special tools to support the JLTV; JLTV spare parts; M205 gun mounts; basic issue items for CROWS; CROWS DCP retrofit kits; AN/VRC-104 radio kits; 16 port network switch kits; Silent Watch energy storage kits; DVE installation kits; M4A1 detector kits; M1114 turret rings and hatches; Maintenance Support Devices, or MSD, with wireless at-platform test sets; Driver's Vision Enhancer, or DVE, sensor modules; display control modules; bracket assembly; electronics components assembly; CROWS appended trainers; CROWS diagnostic kits; CROWS maintenance tool sets; M2 Small Arms Tool Kits; Small Arms MK19 Tool Kits; M2 spare parts; MK93 weapon mounts; Toughbook laptops with interactive electronic technical manuals, or IETM, and cables; JLTV contractor spare parts support; CROW Systems spare parts support; Maintenance Support Items in support of MK19; MK19 Mod III spare parts support; CROWS spare parts; CROWS Basic Issue Items boresight kit components; Total Package Fielding; Field Service Representative support; U.S. government technical assistance; training; technical publications/manuals; and other related elements of logistics and program support. The estimated cost is $250M. The principal contractors will be Oshkosh Corporation and Oshkosh Defense, LLC in Oshkosh, Wisconsin. There are no known offset agreements in connection with this potential sale.

15:03 EDT Novartis' Sandoz announces multi-year partnership with Just - Evotec Biologics - Sandoz, a Novartis division, announced a multi-year partnership with Just - Evotec Biologics, the Seattle-based subsidiary of Evotec SE. "The agreement covers the development and manufacture of multiple biosimilar medicines with an option for expansion and is the most recent step towards strengthening the Sandoz foundation as a stand-alone off-patent medicines company. Access to Just - Evotec Biologics' highly efficient drug substance development platform and manufacturing technology complements Sandoz capabilities, supporting expansion of the current pipeline from 15+ to 24 assets and the continued development of its early-stage biosimilar pipeline," Sandoz stated.

14:51 EDT Nikola shares plunge 15% after quarterly report, exit from European JV - Shares of electric heavy truck maker Nikola (NKLA) are down 15.2% or 15c per share to 83c in late afternoon trading on Tuesday after reporting a first quarter net loss of 26c, in line, on revenue of 11.12M against consensus of $12.15M. " Also, prior to its earnings release the EV maker said that the Iveco Group will assume full ownership of the joint venture in Ulm, Germany. The company will now focus on the North American market, hydrogen fuel cell trucks, the HYLA hydrogen refueling business, and autonomous technologies. Other publicly traded companies in the EV space include: Tesla (TSLA), Fisker (FSR), Rivian Automotive (RIVN), and Workhorse (WKHS).

14:33 EDT Fox Corp. authorizes $7B stock repurchase program - The Company has authorized a $7B stock repurchase program. To date, the company has repurchased approximately $3.4B of its Class A common stock and approximately $1B of its Class B common stock.

13:47 EDT Tenet Healthcare CFO says 'off to a good start to the year' - Asked by a BofA Securities analyst whether the company's guidance "doesn't really seem to assume" that strong EBITDA performance in Q1 persists, Tenet Healthcare CFO Daniel Cancelmi replied, according to a transcript of the Bank of America Healthcare Conference: "Well, we exceeded our EBITDA guidance in the first quarter by roughly $57M. And we raised our guidance by $50M. So we effectively raised our guidance for the first quarter beat. And USPI was raised $20M in the hospitals, we raised $30M. Listen, we're off to a good start to the year, all businesses -- all three of the businesses. And obviously, we're very encouraged, but it's early... and we'll update the guidance appropriately when we get to the end of the second quarter and see where we're at."

13:39 EDT Cuentas Inc trading resumes

13:28 EDT Cuentas Inc trading halted, volatility trading pause

13:04 EDT Tonix Pharmaceuticals announces 1-for-6.25 reverse stock split - Tonix Pharmaceuticals will effect a 1-for-6.25 reverse stock split of its outstanding common stock. This will be effective for trading purposes as of the commencement of trading on May 10, 2023. The reverse stock split was previously approved by the Board of Directors of Tonix in accordance with Nevada law, under which no stockholder approval is required, and is intended to increase the per share trading price of Tonix's common stock to satisfy the $1.00 minimum bid price requirement for continued listing on The NASDAQ Capital Market. Tonix's common stock will continue to trade on the NASDAQ Capital Market under the symbol "TNXP" and under a new CUSIP number, 890260854. As a result of the reverse stock split, every six and one-quarter pre-split shares of common stock outstanding will become one share of common stock. The reverse stock split will also proportionately reduce the number of shares of authorized common stock from 1 billion to 160 million shares. The reverse split will also apply to common stock issuable upon the exercise of Tonix's outstanding warrants and stock options.

12:33 EDT Turkcell trading resumes

12:01 EDT Talos Energy falls -16.0% - Talos Energy is down -16.0%, or -$2.10 to $11.05.

12:00 EDT Genius Sports rises 18.2% - Genius Sports is up 18.2%, or 74c to $4.80.

12:00 EDT Aris Water Solutions rises 21.5% - Aris Water Solutions is up 21.5%, or $1.55 to $8.76.

11:56 EDT Turkcell trading halted, news pending

11:25 EDT Hologic up 3% after U.S. task force recommends earlier breast cancer screening - The U.S. Preventive Services Task Force has posted a draft recommendation statement on screening for breast cancer and now recommends that all women get screened for breast cancer every other year starting at age 40. "This is a B grade. More research is needed on whether or not women with dense breasts should have additional screening with breast ultrasound or MRI, and on the benefits and harms of screening in women older than 75. These are I statements. The use of the term women in this draft recommendation includes cisgender women and other people assigned female at birth," stated the group. In morning trading following the announcement of the task force's recommendation, shares of screening test maker Hologic are up $2.78, or 3%, to $85.88. Reference Link

11:13 EDT Boeing reports 26 commercial airplane deliveries, 34 orders in April - On its website, Boeing reported receipt of 34 commercial airplane gross orders in April and 26 airplane deliveries in April. For the year-to-date, Boeing reports 156 deliveries and 154 gross orders, or 69 year-to-date orders net of cancellations/conversions, and reports 5,343 unfilled orders as of April 30. Reference Link

10:33 EDT Adtran CEO: Longer-term growth outlook remains unchanged - Comments taken from Q1 earnings conference call.

10:18 EDT Guardant Health presents additional data from ECLIPSE study - Guardant Health presented additional data from the ECLIPSE study at 2023 Digestive Disease Week titled, "Clinical Validation of a Cell-Free DNA Blood-Based Test for Colorectal Cancer in an Average Risk Population" showcasing the performance of its blood-based technology to accurately detect early-stage colorectal cancer. The ECLIPSE study is an over 20,000 patient registrational study evaluating the performance of the Shield blood test for detecting CRC in average-risk adults. The data presented at DDW elaborates on the top-line data the company announced in December 2022. Data presented today include: 83% sensitivity in detecting individuals with CRC; 81% sensitivity in detecting Stages I-III; 72% sensitivity in detecting localized disease; and Sensitivity by stage of 55% for Stage I, 100% for Stage II, 100% for Stage III, and 100% for Stage IV. These results are in range with other guideline recommended non-invasive screening modalities, where overall sensitivity ranges from 74-92%. The ability to detect cancers in early stages is an important test parameter as the five-year survival rate is higher when caught early.1 Shield's sensitivity of detecting stage I-III cases and localized cases is in range with other guideline-recommended non-invasive screening modalities.

10:10 EDT Cytomed enters collaboration with MD Anderson Cancer Center - CytoMed Therapeutics has entered into a research collaboration agreement with The University of Texas MD Anderson Cancer Center in Houston, Texas, to use gamma-delta T cells for the treatment of acute myeloid leukemia and breast cancer. AML is the most common type of acute leukemia in adults and is likely to worsen quickly if untreated. However, there are not many treatment options available for AML. Similarly, the incidence rate of breast cancer globally is high, and patients may quickly run out of treatment options, especially if they suffer from triple-negative breast cancer. This collaboration aims to develop new treatment modalities for unmet needs of AML and breast cancer patients at an affordable cost. The study will be led by Venkata Lokesh Battula, Ph.D., associate professor of Leukemia at MD Anderson. Under the terms of the two-year agreement, research teams will evaluate the application of CytoMed's allogeneic gdTc on various subtypes of AML and breast cancer in vitro and in vivo. The study is expected to use patient-derived AML cells and breast cancer cell lines for investigation. The results of the study are intended to be part of an Investigational New Drug Application with the U.S. Food and Drug Administration for the allogeneic use of gdTc for blood and solid cancers. CytoMed received approval in January 2023 from Singapore's Health Science Authority to conduct a first-in-human Phase I clinical trial for the use of its lead allogeneic chimeric antigen receptor T-cell product candidate against several blood and solid tumor cancers, including colorectal, lung, liver, ovarian, lymphoma and multiple myeloma. This is a single-site, open-label, dose-escalating trial at the National University, Hospital, Singapore, an established major public hospital.

10:03 EDT Northern Trust appointed by Artemis for middle office outsourcing - Northern Trust has been appointed to provide a range of whole office outsourcing solutions for Artemis, a leading United Kingdom-based asset manager with more than GBP 24.3B in assets under management. The deal sees Northern Trust appointed as Artemis' single provider of asset servicing solutions. Artemis offers a range of funds that invest in the UK, Europe, the US and around the world. It is a dedicated, active investment house specializing in providing investment management services for both retail and institutional investors. Its agreement with Northern Trust includes the provision of investment operations outsourcing solutions, fund administration, depositary, global custody, and transfer agency services for Artemis' Luxembourg and UK domiciled fund ranges.

10:00 EDT Talos Energy falls -17.6% - Talos Energy is down -17.6%, or -$2.31 to $10.85.

10:00 EDT Palantir rises 13.4% - Palantir is up 13.4%, or $1.03 to $8.78.

10:00 EDT Genius Sports rises 17.7% - Genius Sports is up 17.7%, or 72c to $4.78.

09:48 EDT Hestia announces Pitney Bowes stockholders voted to elect four nominees - Hestia Capital Management, which is the third largest stockholder of Pitney Bowes and holds a 9.1% stake, commented on the outcome of the Company's 2023 Annual Meeting of Stockholders. At the Annual Meeting, stockholders voted to elect four of Hestia's candidates - Milena Alberti-Perez, Todd Everett, Katie May and Kurt Wolf - to the Company's nine-member Board of Directors. Wolf, the Founder and Chief Investment Officer of Hestia, stated: "We greatly appreciate our fellow stockholders for voting to elect four Hestia-nominated director candidates at this year's Annual Meeting. We also want to thank the many stockholders who took the time to engage in thoughtful two-way conversations with us in recent weeks and months. That engagement will benefit the four of us as we enter the boardroom and start working with the incumbent directors to spur a value-generating turnaround at Pitney Bowes. Now that this election contest is over, all of our time can be devoted to strengthening the Company. Our slate believes it has been given a mandate for constructive, positive change - and we look forward to working with our fellow directors to deliver on that mandate over the near-term and long-term. On a personal note, I want to take this opportunity to thank the departing directors for their commitment and years of service to Pitney Bowes. Along with the remaining directors, they have been true champions of Pitney Bowes and its storied brand. I also want to conclude by reaffirming that I will not be accepting Board fees or seeking expense reimbursement for costs incurred in recent months, to ensure that my interests are perfectly aligned with my fellow stockholders. This was a pledge I made to my fellow stockholders, and one that I will absolutely keep."

09:47 EDT CVG conducting comprehensive search for permanent president and CEO

09:47 EDT 3D Systems falls -11.9% - 3D Systems is down -11.9%, or -$1.08 to $8.01.

09:47 EDT Genius Sports rises 10.8% - Genius Sports is up 10.8%, or 44c to $4.50.

09:47 EDT Trex Company rises 11.3% - Trex Company is up 11.3%, or $6.35 to $62.65.

09:46 EDT CVG announces Harold Bevis resigns from president, CEO role - CVG announced that Harold Bevis is resigning from his role as President and CEO of the company and as a member of the company's Board of Directors effective May 19, 2023 to become CEO of another company. Bevis' resignation did not result from any disagreement with the company on any matter, including any matter relating to its operations, policies or practices. Robert C. Griffin, the Chairman of the Board, is expected to be elected by the Board as the company's interim President and CEO, effective May 19, 2023. Griffin will serve as interim President and Chief Executive Officer until his successor is chosen. The company is in the process of conducting a comprehensive search for a permanent President and CEO and will name Griffin's successor at the completion of the search.

09:45 EDT Save Foods commences large scale commercial pilot with Congeladora Nino - Save Foods announced that it will begin conducting a large scale commercial pilot with Congeladora Nino, a Mexican strawberry packer. Save Foods' collaboration with Congeladora Nino initially began with several smaller scale commercial pilots shortly after the company hosted the LATAM delegation, which was led by the Israel Export Institute in conjunction with PepsiCo, on September 21, 2022 at the company's R&D center in Neve Yarak, Israel.

09:38 EDT Maravai LifeSciences trading resumes

09:33 EDT PulteGroup shareholder Miller Law Firm responds to company's accusations - The Miller Law Firm released the following statement from PulteGroup Shareholder Betty Trester in response to accusations made by the company: "I am hurt that PulteGroup has claimed I am not a shareholder of this company since I just voted in their annual meeting and provided them copies of my account statement showing that I own the stock. I am a Marine corps veteran, and my integrity means the world to me. It's worrisome that PulteGroup does not respect individual shareholders like me. Instead of using insulting tactics to avoid corporate transparency, the Company should release the investigative documents to the shareholders of this company today."

09:26 EDT VirnetX announces partnership with Samsung - VirnetX (VHC) announced that it has signed an agreement with Samsung (SSNLF) to resell Samsung's digital display products, including the Samsung Interactive Pro, to create secure conferencing and collaboration spaces for the hybrid workforce in offices, co-working spaces and classrooms using VirnetX One family of products including War Room and VirnetX Matrix.

09:22 EDT Pressure BioSciences announces additional consumer focus group testing - Pressure BioSciences announced results from additional consumer focus group testing of a THC Nanoemulsion Oral Spray designed for rapid, direct absorption through the cheeks. The THC Nanoemulsion Oral Spray was prepared using PBI's revolutionary Ultra Shear Technology platform by PBI's California-based partner companies, including Creme De Canna, a CA-licensed manufacturer and long-established provider of innovative, high-quality cannabis products. Additional consumer focus group testing more than doubled the original cohort of participants and has strongly affirmed multiple pivotal results on the UltraShear processed Nano-THC Oral Spray being powerfully differentiated from traditional THC dosing alternatives: Speedy onset of first effects versus typical THC edibles requiring 30-60 minutes. Much faster progression to maximum effects versus typical THC edibles requiring 60-120 minutes. Eliminates health issues associated with smoking or vaping. Enormous efficiency improvement in dose payload delivery allows equal to much better/greater THC experience from dosing down to a small fraction of user's normal dosing levels. Stable, all plant formulation is sterile packaged with no added preservatives. Multiple testers applied even a single spray to painful body areas and reported fast to instant transdermal pain relief.

09:19 EDT Pizza Inn reenters Texoma Market with Sherman restaurant - Pizza Inn announced the return of Pizza Inn to the Texoma region of North Texas with the opening of a new restaurant in Sherman. The family-focused dine-in buffet is reintroducing the market to its numerous signature pizzas, traditional pastas, and distinctive desserts, called Pizzerts, as well as its robust, all-you-can-eat, fresh salad bar, filled with an array of house-cut ingredients, popular toppings, and six different dressings, including house-made ranch.

09:18 EDT Rackspace Technology appoints Betsy Atkins, Tony Scott to board - Rackspace Technology (RXT) announced the appointment of Betsy Atkins and Tony Scott to its board of directors, effective June 16, 2023. Dhiren Fonseca, who has served on the board since 2016, will step down to focus on other commitments also effective June 16, 2023. Atkins is a three-time CEO and entrepreneur, co-founding enterprise software companies in the tech and consumer industries. Scott is currently CEO of Intrusion (INTZ).

09:15 EDT Biofrontera Inc. collaborates with The Skin Cancer Foundation - Biofrontera announced that as part of several Skin Cancer Awareness Month activities taking place throughout the month of May, it is collaborating with The Skin Cancer Foundation to support sun safety awareness and educate the public on pre-cancer and skin cancer prevention, early detection and effective treatment. A key to skin cancer prevention is diagnosing and treating the most common pre-cancer, actinic keratosis. Biofrontera is working closely with the Foundation to help raise awareness of AK, a disease that affects 58 million Americans and, left untreated, may develop into squamous cell carcinoma, a life-threatening skin cancer. AK forms on skin damaged by chronic exposure to ultraviolet rays from the sun and/or indoor tanning. Education and awareness are high priorities for both organizations and are essential to minimize this preventable disease. As part of this effort, this year The Skin Cancer Foundation designated May 17 as the day to focus on awareness of AK as a pre-cancer during their Skin Cancer Awareness Month activities.

09:14 EDT Amazon Studios acquires worldwide rights to 'The Blue Angels' - Amazon Studios has acquired worldwide rights to the IMAX Original Documentary, "The Blue Angels." Bad Robot, Glen Powell's Barnstorm Productions, Zipper Bros Films, and Dolphin Entertainment produced the project that chronicles a year in the cockpit with one of the most exclusive aviator teams in the world, filmed with awe-inspiring IMAX cameras. "The Blue Angels" follows the newest class of the storied Navy and Marine Corps flight squadron through intense training and into a season of heart-stopping aerial artistry, and the veterans on the team who, this year, will take their final flights. It marks the first time the iconic blue and yellow F/A-18 Super Hornets will be featured in IMAX. The film also captures the spectacle of this traveling air show through key members of the support staff on the ground, as well as from loved ones left at home.

09:11 EDT Advent Technologies, BASF Environmental Catalyst enter supply chain pact - BASF Environmental Catalyst and Metal Solutions and Advent Technologies, an innovation-driven leader in the fuel cell and hydrogen technology sectors, have concluded the terms of a new agreement to join efforts in building a full loop component supply chain for fuel cells and enter discussions to extend the partnership into the field of water electrolysis.

09:09 EDT Beyond Meat's Beyond Steak certified by AHA's Heart-Check Program - Beyond Steak, an innovation made by Beyond Meat, is now certified by the American Heart Association's, AHA, Heart-Check Food Certification Program. Beyond Steak joins the ranks of a select number of products that meet the American Heart Association's exacting nutrition criteria to help people make informed choices about the food they purchase. "For nearly 100 years, the American Heart Association has been helping people live longer, healthier lives. As part of that legacy, the Heart-Check Mark has become a gold standard in empowering consumers to make informed health decisions," said Beyond Meat CEO Ethan Brown. "Like the American Heart Association, we want to be part of the solution by providing individuals access to and resources on nutritious options that don't compromise on taste or sustainability. With this recognition, Beyond Steak becomes part of a group of certified and trusted foods that everyone can enjoy with the confidence that they are making a great decision for their health."

09:09 EDT Pfizer, Thermo Fisher enter pact to expand access to NGS-based testing - Pfizer (PFE) and Thermo Fisher (TMO) announced they have entered into a collaboration agreement to help increase local access to next-generation sequencing, or NGS-based testing for lung and breast cancer patients in more than 30 countries across Latin America, Africa, the Middle East and Asia where advanced genomic testing has previously been limited or unavailable. Access to local NGS testing can help to provide faster analysis of associated genes, empowering healthcare providers to select the right therapy for that individual patient.

09:09 EDT Wendy's and Google Cloud partering to launch AI drive-thru solution - Wendy's (WEN) and Google (GGOG) Cloud announced an expanded partnership to pilot an artificial intelligence solution, Wendy's FreshAI, to transform Wendy's drive-thru food ordering experience with Google Cloud's generative AI and large language models technology. In June, Wendy's plans to launch its first pilot of Google Cloud's AI technology in a Columbus, OH-area, company-operated restaurant, using those learnings to inform future expansions to more Wendy's drive-thrus. The pilot will include new generative AI offerings, such as Vertex AI and more, to have conversations with customers, the ability to understand made-to-order requests and generate responses to frequently asked questions. This will all be powered by Google's LLMs that have the data from Wendy's menu, established business rules and logic for conversation guardrails, and integration with restaurant hardware and the Point of Sale system.

09:07 EDT Tremor International enters global partnership with Scope3 - Tremor International announced a global partnership with Scope3, the source of truth for supply chain carbon emissions data, which, in a first for the market, sees Scope3's carbon emission measurement methodology applied to CTV inventory. Through Unruly, the SSP in Tremor's platform, buyers can access Green Media Product curated deals - powered by Scope3 data - across premium display, video and now, CTV, to achieve performance goals while mapping and measuring the carbon emissions of their media spend.

09:06 EDT Borqs Technologies engages Cantor Fitzgerald for divestment of Holu Hou Energy - Borqs Technologies has engaged Cantor Fitzgerald & Co. as its exclusive financial advisor with respect to the divestment of the Company's ownership in Holu Hou Energy, a fast-growing solar energy and storage provider with unique solutions in energy sharing for the multi-dwelling residential market.

09:04 EDT Amgen and TScan Therapeutics partner for Crohn's Disease target identification - Amgen (AMGN) and TScan Therapeutics (TCRX) announced a multi-year collaboration that will use TScan's proprietary target discovery platform, TargetScan, to identify the antigens recognized by T cells in patients with Crohn's disease. Under the terms of the agreement, TScan will receive a $30M upfront payment and is eligible to earn over $500 million in success-based preclinical, clinical, regulatory and commercial milestones as well as tiered single-digit royalty payments. Amgen will evaluate a variety of modalities to create therapeutics based on targets discovered by TScan and will retain all global development and commercial rights. Amgen also has an option to expand the collaboration to ulcerative colitis, under certain terms. Each party will be responsible for its own research expenses.

09:03 EDT Boeing, Ryanair confirm Ryanair order for 300 Boeing 737 MAX-10 aircraft - Boeing (BA) and Ryanair (RYAAY) announced Europe's leading low-cost airline has selected the largest 737 MAX model to power its future growth with an order for up to 300 airplanes. The purchase agreement is the biggest in Ryanair's history and includes a firm order for 150 737-10 jets and options for 150 more.

09:01 EDT Allbirds releases first golf shoe, the Golf Dasher - The company said, "Allbirds is taking to the golf course for the first time, with its new shoe, the Golf Dasher. The shoe builds on the comfort, sustainable materials, and fit of Allbirds's Dasher silhouette, with added elements like traction and water-repellent materials for on-course performance. Whether you're playing a round or buying a round, the Golf Dasher offers a supremely comfortable, greener option for the course."

08:59 EDT Bragg Gaming launches new content with Rush Street Interactive in Pennsylvania - Bragg Gaming (BRAG) announced that it has launched its new content and technology with Rush Street Interactive (RSI) in Pennsylvania. This launch, which builds on the company's Spin Games content that is already live in the state, introduces the company's new, proprietary Bragg Studios content to a large and growing U.S. jurisdiction. This demonstrates continued progress with the Company's North American expansion as RSI is one of the leading iGaming operators in the U.S., Canada and Latin America.

08:57 EDT Summit Therapeutics doses first patient in HARMONi study - Summit Therapeutics announced that the first United States-based patient has been enrolled in the Phase III HARMONi study.

08:56 EDT Cybin completes dosing in Part B of CYB004-E trial - Cybin announced the completion of dosing the last subject in Part B of its three-part CYB004-E Phase 1 trial evaluating intravenous N,N-dimethyltryptamine, or IV DMT, in healthy volunteers. With the achievement of this milestone, Cybin intends to initiate Part C of the study, the first-in-human dosing of its proprietary DMT molecule CYB004.

08:55 EDT Jaguar Health completes enrollment in Phase 3 OnTarget trial of crofelemer - Jaguar Health announced that it has completed enrolling the target number of 256 patients in the Company's global, pivotal, Phase 3 OnTarget clinical trial of crofelemer for prophylaxis of diarrhea in adult cancer patients receiving targeted therapy with or without chemotherapy. "The Company's current cash position includes anticipated gross proceeds from a PIPE transaction of approximately $1.86 million involving the issuance and sale of approximately 3,425,000 shares of unregistered Jaguar Common Stock and 6,850,000 warrants not exercisable until the later of January 1, 2024 and stockholder approval, that is expected to close on May 9, 2023, subject to customary closing conditions," said Lisa Conte, Jaguar's president and CEO. "This financing involves a small group comprised primarily of dedicated, long-term Jaguar investors. Pursuant to the terms of the PIPE purchase agreement, each participating investor agreed not to sell or transfer any Jaguar equity securities for a period commencing on the signing of the Agreement and ending six months after the PIPE closing. There are no anti-dilution, reset, or variable pricing rights associated with the securities issued in the PIPE. We believe this financing illustrates the confidence that the participating investors have in the Company and the expectation that both the OnTarget trial and our focus on development of proof-of-concept data for crofelemer for the rare disease indications of short bowel syndrome with intestinal failure and congenital diarrheal disorders will prove transformational in 2023 for Jaguar value recognition." The exercise of the warrants included in the PIPE is subject to shareholder approval. The Agreement also provides that during the period commencing on the signing of the Agreement and ending on October 22, 2023, the Company will not effect or enter into any agreement to issue securities in exchange for any securities of the Company issued and outstanding on the date of the Agreement pursuant to Section 3(a)(9) of the Securities Act of 1933, as amended, including ATM utilization or effect issuance by the Company of common stock or common stock equivalents, subject to certain customary carve outs set forth in the Agreement or with the consent of holders of a majority of shares issued in the PIPE. The Company plans to use the proceeds from the PIPE transaction to fund Company operations and support the ongoing operation of the OnTarget trial.

08:54 EDT MultiPlan acquires advanced analytics company Benefits Science for $160M - MultiPlan announced that it has acquired Benefits Science or "BST , a next generation data and advanced analytics company that combines modern data science, including machine learning and artificial intelligence with deep expertise in healthcare to deliver solutions that reduce the cost of care and improve health outcomes. This acquisition will combine the capabilities of two leaders in the healthcare arena to provide cutting edge, differentiated solutions to customers across a full spectrum of healthcare channels and markets through our new Data & Decision Science service line...Under the transaction agreement, MultiPlan will pay a consideration of $160M, comprised of $140.8M in cash and 21.6M shares of MultiPlan common stock to acquire BST. Additionally, MultiPlan will establish a long-term incentive and retention program pursuant to which BST's management team is eligible to receive target payments of $66M over three to five years, subject to ongoing service to MultiPlan and to adjustments based on performance relative to annual recurring revenue targets. For the full year 2023 on a standalone basis, BST is projected to generate revenues of approximately $16M with breakeven profitability. MultiPlan expects the acquired company to contribute over $100M of incremental annual revenues within the next several years and to approach corporate-level profit margins at scale.

08:51 EDT NeoVolta's backup system saves MDX Labs' medications during grid outages - NeoVolta has kept MDX Labs protected during multiple grid outages with reliable battery backup. "Being able to support commercial facilities that are powered with 208-volt electricity is an amazing capability. Transformers are not required, which saves customers thousands of dollars and eliminates loud equipment that gives off radiant heat," said Brent Willson, CEO of NeoVolta. "Our energy storage solutions are a very smart investment, especially considering the cost and consequence of an outage that would result in the loss of vital medical supplies and medications. We are thrilled to be partnering with MDX, a world-class clinical diagnostic laboratory."

08:51 EDT Black Hills natural gas utility requests rate review in Colorado - Black Hills announced that its Colorado natural gas utility, Black Hills Colorado Gas, doing business as Black Hills Energy, filed a rate review application with the Colorado Public Utility Commission requesting $26.7M in new annual revenue. Black Hills Energy has invested approximately $140M in system safety, integrity and reliability for more than 10,000 miles of natural gas utility infrastructure in Colorado since its last rate review request in 2021. These critical investments ensure the safe and reliable delivery of natural gas and transportation services and meet compliance requirements of state and federal regulations. "This rate review request supports our ability to serve our Colorado customers with, safe, reliable and clean natural gas service," said Linn Evans, president and CEO of Black Hills Corp. "Our investments support a resilient natural gas system with lower emissions to achieve our emissions reduction targets, which support Colorado's clean energy goals. We are very mindful of customer bill impacts and are focused on cost-effective service and ways to help reduce volatility in bills."

08:46 EDT Neogen launches new assays for natural toxin detection - Neogen has launched two new assays for the detection of natural toxins, Reveal Q+ for DON EndPoint and Reveal Q+ for Aflatoxin EndPoint. Designed to be read on Neogen's Raptor(R) Solo Platform, the EndPoint assays are intended for use in situations where increased workflow output is needed. Both assays have received a Federal Grain Inspection Service (FGIS) Certificate of Compliance for corn and wheat commodities, certifying that the tests meet all of the USDA-FGIS's design and performance standards and can be used for official inspections.

08:44 EDT Diversified Energy reports Q1 average daily production 139 MBoepd - Delivering Reliable Results: Recorded average 1Q23 production of 139 Mboepd; Exit rate of 145 Mboepd; Includes 15% liquids; Up 30% since entering Central Region; Net income of ~$400 million inclusive of a ~$365 million gain on tax-effected, non-cash unsettled derivative fair value adjustments; Achieved 1Q23 Adjusted EBITDA of ~$150 million; Realized 54% Cash Margin benefiting from lower expenses; Annualized Free Cash Flow Yield of ~37%; Total Unit Cash Expense of $10.46/Boe; ~6% improvement compared to 4Q22; 2.3x Net Debt / Adjusted EBITDA leverage ratio and ~$110 million of liquidity. Executing Strategic Objectives: Declared 1Q23 interim dividend of 4.375 cents per share, consistent with 4Q22; up 3% vs. 1Q22; Completed Tanos II asset acquisition; Maintained favorable natural gas hedge position; 2023 average floor pricing 35% above strip for remainder of 2023; Completed ~$6 million in non-core undeveloped acreage sales across the Company's operating footprint.

08:42 EDT Origin Bancorp announces transfer of listing of common stock to NYSE - Origin Bancorp, the parent company of Origin Bank, announced that it is transferring the listing of its common stock to the New York Stock Exchange, NYSE, from The Nasdaq Stock Market. Origin's common stock is expected to begin trading on the NYSE on Monday, May 22, 2023, under the new ticker symbol of "OBK". Origin expects its common stock to continue to trade on Nasdaq until the close of the market on May 19, 2023. "We are excited to take this next step in our journey as a public company. Since our founding in 1912, we have been committed to providing meaningful value to our employees, customers, communities and shareholders," said Drake Mills, chairman, president and CEO of Origin. "As a sophisticated and agile community bank serving communities across Texas, Louisiana and Mississippi, we look forward to joining many of the world's leading and most prestigious companies that trade on the NYSE and are excited to leverage the NYSE platform and trading model for the benefit of our shareholders."

08:40 EDT Ryanair announces order for 300 Boeing 737 MAX-10 aircraft

08:40 EDT Can-Fite BioPharma to initiate Namodenoson trial - Can-Fite BioPharma announced that it will initiate an open-label Phase 2 exploratory trial to assess the efficacy and safety of Namodenoson in the treatment of patients with pancreatic cancer who have received at least one previous systemic therapy.

08:38 EDT PureCycle Technologies provides corporate update for Q1 - The Company's flagship purification facility in Ironton is certified mechanically complete, has completed the pre-startup PSM certification required for solvent deliveries and all core operating systems have been commissioned and are ready for startup. The first solvent delivery was received, and the Company expects to start producing pellets from virgin resin feedstock in the next few weeks. We will then plan to introduce post-industrial and post-consumer feedstock into the purification process and begin producing UPR resin pellets for sale and distribution to customers. PureCycle's ramp-up strategy is to gradually increase plant capacity utilization while scaling in higher volumes of feedstock deliveries and customer offtake shipments. Management remains confident that PureCycle will achieve the operational milestones as set out in the bondholder limited waiver agreement executed in March in a timely manner. PureCycle continued to make progress on its various development projects since its last update. Site engineering work is progressing for the Company's Augusta location and module preparation for construction has commenced in Beaumont, Texas. Updates on our three international development projects include: the PureCycle team in Belgium has initiated site engineering work at the Port of Antwerp to start the permitting process; our joint venture team in South Korea continued to progress on engineering plans in accordance with the priorities defined by the joint venture; and (iii) we continued our JVA discussions with Mitsui, while the joint venture team has started the feasibility study process on potential purification plant locations in Japan. As of March 31, 2023, PureCycle had total liquidity of $263.9 million including $38.4 million of cash and cash equivalents and $225.5 million in restricted cash. PureCycle also had $249.6 million in debt, less $15.8 million of discount and issuance costs. As of March 31, 2023, PureCycle estimated between $26-$51 million remaining investment in 2023 to complete the Ironton project, of which $25.2 million is included in restricted cash and can be used to fund the remaining investment. This puts the higher end of the project investment at approximately $361 million. This range is dependent upon various contract contingencies and their ultimate resolution. PureCycle expects to successfully negotiate at least some of these contingencies, which would reduce the remaining 2023 investment to the lower end of the range. Subsequent to quarter end, PureCycle closed on an equipment financing agreement for up to $22 million which is secured by Augusta PreP wash equipment. The lease has a term of 36 months, a 7% interest rate and flexible end-of-lease terms. Additionally, the Company secured a $40 million term loan with an entity controlled by Dan Gibson, the Chief Investment Officer of Sylebra Capital, PureCycle's largest shareholder. The loan matures on December 31, 2025, and bears interest at a floating rate of SOFR + 7.5%.

08:36 EDT Bowlero appoints Bobby Lavan as CFO - Bowlero (BOWL) announced the appointment of Bobby Lavan as Chief Financial Officer. Brett Parker, Bowlero's long-term Vice Chairman, President and Chief Financial Officer, will remain Vice Chairman and President of Bowlero. Lavan will join the Company on May 11, as Chief Financial Officer Designate, and is expected to assume the role of Chief Financial Officer on May 18, the day after the Company plans to file its Quarterly Report with the SEC. Lavan will lead the Company's finance, accounting, and treasury organization, and will report directly to Mr. Parker. Lavan has been Chief Financial Officer and an executive of the finance team of NYSE-listed Bally's Corporation (BALY)

08:36 EDT Digital Turbine adds SingleTap app install to Google Cloud - Digital Turbine announced an expansion of its partnership with Google Cloud to deliver DT's SingleTap technology to app developers. Available on Google Cloud Marketplace, DT SingleTap enables frictionless app installs from any mobile ad placement. Developers leveraging Google Cloud will be able to offset the percentage of spend of SingleTap dollars towards their Google Cloud commitments. Developers can also choose from both SDK and non-SDK integration options when adding SingleTap capabilities to their apps.

08:34 EDT NetSol Technologies launches Hubex API Library - NETSOL Technologies announced the launch of Hubex, an API library that enables companies to standardize all their API integration procedures across multiple API services through a single integration. Hubex is NETSOL's second product offering from the AppexNow marketplace following Flex, an API-based, ready-to-use calculation engine.

08:33 EDT SAB announces progress on U.S FDA's review of DiversitAb platform - SAB Biotherapeutics announced the U.S. Food and Drug Administration, FDA, has approved five of seven sections required for the Company's pending New Animal Drug Application, NADA, for the company's antibody-generating platform in Transchromosomic bovine. SAB is in the process of completing the remaining two sections of the NADA. Upon formal acceptance of the seven-step safety and effectiveness evaluation, the company will use this approval in support of Biologics License Applications, BLAs, with the FDA Center for Biologics Evaluation and Research, CBER, for its hIgG antibody investigational drugs. "SAB is the only company in the world progressing this kind of advanced genetic engineering to develop rapid, scalable production of highly potent, fully-human polyclonal IgG antibodies, without the need for human donors," said Eddie Sullivan, Ph.D., co-founder, President, and Chief Executive Officer of SAB Biotherapeutics. "The FDA has an established regulatory pathway to review our cutting-edge science, and we are pleased to be making significant progress. This process is a one-time approval that will be applicable for all subsequent investigational products produced from the DiversitAb platform using our transchromosomic bovine. SAB is focused on a successful completion of NADA to rapidly pursue BLA approvals for our investigational therapeutics."

08:32 EDT Greenland Technologies' HEVI subsidiary appoints Dana Hopkins as COO - Greenland Technologies appointed Dana Hopkins as COO of HEVI, a wholly owned subsidiary of Greenland, effective March, 2023. Hopkins has served in roles such as COO at the Western Carolina Forklift and Toyota Material Handling Northeast along with other executive roles in companies such as Hangcha Forklift of America, The Modern Group, Pacific Material Handling Group and Eastern Lift Truck Company. Most recently, he served as Customer Experience Manager at JESCO.

08:31 EDT Baxter CFO Jay Saccaro leaving at end of May, Brian Stevens named interim - Baxter International announced the departure of executive vice president and chief financial officer CFO Jay Saccaro. Saccaro will leave Baxter at the end of May after 21 cumulative years with the company, including the past eight as CFO, to join a company in the healthcare industry. Baxter has named Brian Stevens as acting CFO, effective May 31 while the company conducts its search to fill the role. Mr. Stevens joined Baxter in 2018 as senior vice president, chief accounting officer and controller, and will continue with these responsibilities in addition to serving as acting CFO. He joined Baxter from Groupon, where he most recently served as treasurer and chief accounting officer. Prior to Groupon, Mr. Stevens spent the majority of his career with KPMG, where he was most recently an audit partner. "It has been a privilege to work at Baxter and help fulfill its mission," said Saccaro. "I am confident that Brian's significant leadership experience in finance and accounting roles and the deep understanding of our business he has built will position him well to take on the role of acting CFO after my departure."

08:27 EDT Clear Secure declares 20c per share special dividend - Clear Secure announced that a special committee of its board of directors has approved and declared a special cash dividend in the amount of 20c per share, payable on May 25, to holders of record of Class A Common Stock and Class B Common Stock as of the close of business on May 18.

08:26 EDT Catalyst Pharmaceuticals advances sNDA submission plans - Catalyst Pharmaceuticals reported that it recently concluded a Type C meeting with the U.S. Food and Drug Administration, FDA, regarding its plans to file a supplemental New Drug Application, sNDA, to increase the maximum daily dosage of FIRDAPSE from 80mg to 100mg for the treatment of Lambert Eaton myasthenic syndrome, LEMS. Based on the feedback received from the meeting, Catalyst believes it now has the information necessary to complete the submission of its sNDA for marketing approval in the U.S. early in the third quarter of 2023. "The meeting was held for alignment of our strategy to support a proposed maximum 100-milligram daily dose indication of FIRDAPSE," said Patrick J. McEnany, Chairman and Chief Executive Officer of Catalyst. "We thank the Agency for their collaboration in reviewing our submitted materials and providing their feedback. Based on the positive outcome of the meeting, we remain on track to file an sNDA submission early in the third quarter of 2023. If approved, we believe this change will address an important need for LEMS patients, caregivers, and physicians who may benefit from an optimized therapy."

08:25 EDT Jacobs to spin off Critical Mission Solutions business - Jacobs announced that its board of directors has unanimously approved a plan to separate its Critical Mission Solutions, or CMS, business from Jacobs, creating two independent companies, which generated approximately $4.4B in revenue in fiscal year 2022. Jacobs is committed to maintaining an investment grade profile for Jacobs following the separation. The proposed capital structure, governance and other matters relating to CMS are still being determined and will be communicated at a later date. Jacobs is targeting completing the separation in the second half of fiscal year 2024 through a distribution that is intended to be tax-free to Jacobs shareholders for U.S. federal income tax purposes. Completion of the separation transaction is subject to final approval by Jacobs' Board of Directors and other customary conditions, including the receipt of a private letter ruling from the Internal Revenue Service, opinions from tax advisors and the filing and effectiveness of a registration statement with the U.S. Securities and Exchange Commission. Jacobs intends to provide updates on the separation as appropriate.

08:25 EDT AMC Networks reports streaming subscribers grew 22% from prior year to 11.5M - Streaming subscribers grew 22% from the prior year to 11.5M subscribers as of March 31.

08:24 EDT TransUnion names Clark as SVP of Media and Entertainment - TransUnion (TRU) announced that Julie Clark has been named Senior Vice President, SVP, of the Media and Entertainment business. TransUnion also announced the evolution of Matt Spiegel's role from Executive Vice President of the Media and Entertainment vertical to a newly created role dedicated to driving growth for TransUnion's TruAudience solution line across the U.S. Prior to joining TransUnion, Clark has held several leadership positions building ad businesses from the ground up. In her most recent role, Clark served as Global Head of Advertising Revenue Innovation at Spotify (SPOT).

08:23 EDT Bally's CFO Bobby Lavan to depart, Marcus Glover to succeed - Bally's announced that Marcus Glover has been appointed as Bally's executive VP and CFO. Bobby Lavan, Bally's current CFO, will be leaving the company to pursue another opportunity. He will be available to management, as needed, to ensure a seamless transition. Glover's appointment is subject to receipt of customary regulatory approvals. Most recently, Glover served as chief strategy officer for QPSI.

08:21 EDT Red White & Bloom Brands issued CTO by British Columbia Securities Commission - Red White & Bloom Brands announces that, it has been issued a Cease Trade Order ("CTO") by the British Columbia Securities Commission by virtue of having not filed the following periodic disclosure documents by the applicable filing deadlines: Annual audited financial statements for the year ended December 31, 2022; Management's Discussion and Analysis for the period ended December 31, 2022; and Certification of annual filings for the period ended December 31, 2022. The delay is due to the complexity of acquisition and disposition transactions resulting in the Company and its auditors not having adequate time and resources available to complete the audit in the allotted time. The Company is collaborating with its auditor, Macias Gini & O'Connell LLP, to complete the audit and issue the disclosures by end of day on May 9, 2023. The Company will issue advice by news release should any further delays be foreseen. The Company continues to operate normally and reports that the cause of the delay is not material to the Company's operations. RWB will issue a news release announcing completion of the requisite filings once posted on SEDAR.

08:20 EDT Mobileye and Porsche in strategic pact on series of ADAS solutions - The sports car manufacturer Porsche (POAHY) and the technology company Mobileye (MBLY) have entered into a strategic collaboration for series production of premium ADAS solutions. In future models, Porsche plans to offer automated assistance and navigate-on-pilot functions based on the Mobileye SuperVision technology platform. "Mobileye is one of the world's leading providers of automated driving functions. This technology will help us forge ahead with our strategy of modern, sporty luxury," says Oliver Blume, Chairman of the Executive Board of Porsche. "We are combining an outstanding product with a highly personal experience. The desires and lifestyles of our customers are important to us. We want to exceed expectations again and again - and that's exactly what we're doing with world-class partners like Mobileye."

08:20 EDT Novavax announces results from COVID-Influenza Combination safety study - Novavax announced that its COVID-Influenza Combination, or CIC, stand-alone influenza and high-dose COVID vaccine candidates all showed a preliminary safety profile as well as comparable reactogenicity to individual Novavax influenza and COVID vaccine candidates or authorized influenza vaccine comparators. Additionally, all three vaccines demonstrated preliminary robust immune responses. The primary endpoint evaluated the safety of different formulations of the CIC vaccine candidate and the quadrivalent influenza vaccine candidate compared to Fluad and Fluzone High-Dose Quadrivalent, as well as a high-dose COVID vaccine candidate in adults aged 50 through 80. All three vaccine candidates contained Novavax's patented Matrix-M adjuvant and showed reassuring preliminary safety profiles and reactogenicity that was comparable to Fluad and Fluzone HD. The reactogenicity profile remained consistent as the adjuvant or antigen dose was increased. In all groups there were no adverse events, or AE, of special interest, no potentially immune mediated medical conditions and no treatment-related serious AEs. Unsolicited AEs occurred in 25% or fewer of any group and were consistent with diagnoses in the older adult population. Local and systemic symptoms were mostly mild and moderate and occurred at rates comparable to Fluad and Fluzone HD. The CIC vaccine candidate achieved both immunoglobulin G, or IgG, and neutralizing levels comparable to Novavax's prototype COVID vaccine. In addition, several of the combination formulations achieved responses to both SARS-CoV-2 and to the four homologous influenza strains that were comparable to the reference comparators, supporting their prioritization for advanced development. The stand-alone influenza vaccine candidate achieved statistically significant hemagglutination inhibition, or HAI, antibody responses 31 to 56% higher for all four strains compared to Fluad. Titers were 44, or H1N1, to 89%, or H3N2, higher for A strains and statistically non-inferior for B-strains compared to Fluzone HD. The highest dose stand-alone COVID vaccine candidate achieved statistically significant anti-S IgG and neutralization responses approximately 30% higher than Novavax's prototype COVID vaccine while maintaining comparable safety and reactogenicity to currently authorized dose level of Nuvaxovid.

08:18 EDT AMSC announces $30M of new energy power system orders - AMSC announced $30M of new energy power systems orders. This includes orders for enclosed capacitor banks, harmonic filters, voltage controllers, rectifiers, D-VAR VVO and transformers. Almost all the revenue from these orders is expected to be recognized in fiscal year 2023. "We are seeing consistent and growing demand for our new energy power systems solutions across a broader range of the industrial market AMSC serves today," said Daniel P. McGahn, Chairman, President and CEO, AMSC. "Of today's announced orders, approximately one-third comes from renewables such as solar and wind, and approximately two-third from industrials including metals, mining and semiconductor projects. We continue to target other opportunities for increased market participation to support our momentum in our Grid segment."

08:18 EDT WillScot Mobile Mini expands offering of blast resistant modules - WillScot Mobile Mini announced it has acquired Hallwood Modular Buildings based in Orange, Texas and BRT Structures based in Alberta, Canada, significantly expanding the Company's specialty modular fleet serving customers in need of protective workspace in blast zones and other demanding environments. Tim Boswell, President and Chief Financial Officer, commented, "Safety is our first core value. We service some of the most discerning industrial customers in North America who choose to do business with WillScot Mobile Mini because of our world-class safety culture, our technical expertise, and our commitment to operational excellence. As we execute our growth strategy, expanding our offering of blast resistant modules aligns perfectly with our customer value proposition, whereby we help our customers be safe, comfortable, and productive in their work environments. Blast resistant modules enable safe growth and development for key sectors of the economy, such as manufacturing, petrochemicals, and defense, where workers can be exposed to potentially hazardous environments. They bring substantial productivity benefits by allowing employees to work safely and in closer proximity to critical infrastructure, while avoiding transit time in and out of blast zones. When combined with our existing fleet of modular space and storage solutions, WillScot Mobile Mini is the most sophisticated and comprehensive supplier of turnkey space solutions for industries that demand the highest standards for safety, service, and reliability. We welcome the Hallwood and BRT teams and the unique expertise they bring to WillScot Mobile Mini."

08:17 EDT Star Equity issues open letter to board of Superior Drilling - Star Equity Fund, an 11.7% shareholder of Superior Drilling Products, issued an open letter to SDPI's Board of Directors, particularly its three independent Board members: James Lines, Robert Iverson, and Michael Ronca. " On May 10, 2022, we wrote an Open Letter to the Board calling on you to run a process to maximize SDPI shareholder value and improve the Company's corporate governance. Since that time, you have done neither. In addition, we nominated two highly qualified candidates to serve on the SDPI Board. Although Mr. Ronca interviewed both candidates, SDPI filed its proxy statement without any mention of considering them and with incorrect and misleading information on our share ownership. Mr. Ronca did not even extend the courtesy of contacting us or our nominees about these candidates not being selected by the Governance committee of the Board. Additionally, we requested a call with the SDPI Board which was scheduled for September 19, 2022. At the last minute, however, all the Board members except for Troy Meier refused to show up for the call, which once again shows disregard for the Company's non-affiliated shareholders... Our frustration is with the three independent Board members: Lines, Iverson, and Ronca, whom we believe are not fulfilling their fiduciary duty to SDPI's shareholders. Consequently, we will vote "WITHHOLD" on Iverson at the 2023 Annual General Meeting of Shareholders. In addition, we call on the Board to effectuate, or at least put up for a shareholder vote, the following matters at the 2023 AGM: 1) Hire a Financial Advisor and Conduct a Strategic Review. We believe strongly that SDPI should become part of a larger entity, so we call on the Board to hire a financial advisor and conduct a strategic review... 2) Agree to Put Any Acquisition Up for a Shareholder Vote... 3) Declassify the Board... 4) Remove Supermajority Vote Requirement... 5) Appoint an Independent Board Chair... 6) Pay Off the Tronco Loan Immediately... We are deeply concerned that the three independent directors don't share our goals of maximizing value for all SDPI shareholders and creating a thriving, well-regarded Company where customers, employees, and shareholders all benefit from its products, services, and overall presence in the marketplace. We urge the Board to promptly effectuate the six items above or, at a minimum, put them up for a shareholder vote at the 2023 AGM."

08:15 EDT TriLink BioTechnologies introduces mRNA capping technology - TriLink BioTechnologies has launched its newest cap analog, CleanCap M6. The latest CleanCap analog is expected to help developers and researchers maximize the impact of their mRNA therapeutics and vaccines while reducing overall manufacturing costs, bringing life-changing medicines to market faster. With the introduction of the CleanCap M6 technology, legacy capping methods like enzymatic and ARCA may be a thing of the past. By combining the modification of 3'OMe on the m7-Guanosine and the additional methyl modification on the +1 Adenosine, the CleanCap M6 analog is expected to improve mRNA potency with the highest protein expression of any CleanCap analog yet. Combined with technology's single-pot reaction capabilities that shrink manufacturing times and increase mRNA yields with a purity profile of greater than95%, CleanCap analogs are novel mRNA Cap structures, which may improve the benefits of an mRNA therapeutic or vaccine.

08:13 EDT Infinera, Sumitomo completes first testing of pluggable transceiver technology - Infinera (INFN) announced it has successfully completed the industry's first testing of point-to-multipoint coherent pluggable transceiver technology in Japan in collaboration with Sumitomo Electric (SMFG). The testing showcased multiple optical transmission demonstrations and the role that XR optics technology can play in helping network operators in Japan cost-effectively keep pace with relentless bandwidth growth driven by 5G, high-speed broadband, cloud-based services, and data center interconnect. XR optics is the industry's first coherent optical solution that can solve the challenges caused by the misalignment between network traffic patterns and the technology used to transport that traffic at the optical layer. Benefits include a significant reduction in total cost of ownership, dramatic network simplification, and an unprecedented level of network flexibility. As members of the industry's Open XR Forum, Infinera and Sumitomo Electric are collaborating to accelerate adoption of intelligent coherent point-to-multipoint network architectures and drive standardization of networking interfaces to ensure ease of multi-vendor interoperability and an open, multi-source solution ecosystem.

08:12 EDT Acrivon Therapeutics announces FDA Fast Track designations for ACR-368 - Acrivon Therapeutics announced that the company has been granted two Fast Track designations by the U.S. Food and Drug Administration for the development of ACR-368 in platinum-resistant ovarian cancer and endometrial cancer. One Fast Track development program designation was granted for the investigation of ACR-368 as a monotherapy treatment for patients with OncoSignature positive, locally advanced, or metastatic, recurrent platinum-resistant high-grade ovarian carcinoma who have received at least one prior systemic treatment regimen. The second Fast Track development program designation was granted for the investigation of ACR-368 as a monotherapy treatment for patients with OncoSignature positive, recurrent high-grade endometrial cancer who have received at least two prior systemic treatment regimens. ACR-368, also known as prexasertib, is a targeted DNA damage response inhibitor therapy. ACR-368 is being studied in a multicenter, open-label Phase 2 clinical trial with single-arm, potentially registrational cohorts of patients with platinum-resistant ovarian cancer, endometrial adenocarcinoma, and urothelial cancers based on OncoSignature-predicted sensitivity to ACR-368. The OncoSignature test is a first-of-its-kind drug-specific companion diagnostic that uses proteomic biomarkers to identify the patients most likely to benefit from a drug candidate. OncoSignature tests are developed using Acrivon's Predictive Precision Proteomics platform, which matches the drug mechanism of action with the critical tumor-driving pathways.

08:11 EDT CymaBay names Shantharam as Chief Financial Officer - CymaBay Therapeutics announced that seasoned biopharma executive Harish Shantharam, CFA has joined the company as Chief Financial Officer. Shantharam brings nearly 20 years of biotech experience leading financial functions with a very strong emphasis on setting strategy and building financial planning and accounting operations to prepare companies for commercial drug launch. Shantharam was most recently the Senior Finance Adviser to the CFO at Eikon Therapeutics.

08:10 EDT Caledonia Mining appoints John Kelly as chairman of the board - Mr Kelly, who was acting as interim chairman of the board of directors following the retirement of Mr Leigh Wilson on May 4, 2023, was appointed as Chairman at a meeting of the board immediately following the AGM. Given the Company's policy that the Chairman shall not be a member of the Audit Committee, another independent non-executive director, Mr Gordon Wylie, was appointed to the Audit Committee in his place.

08:09 EDT Univar signs distribution agreement in Brazil for sun care filters - Univar Solutions Univar Brasil subsidiary announced a distribution agreement with Croda do Brasil, life sciences and consumer care company that creates, makes, and sells specialty chemicals for sun care filters. The addition of Croda's ingredients for sun care filters, used in facial and body lotions formulated with ultraviolet physical filters, expands Univar Solutions' offering of beauty and personal care products in the sun care space.

08:07 EDT Acrivon Therapeutics expects cash to fund operations into 4Q24 - As of March 31, 2023, the company had cash, cash equivalents and marketable securities of $159.5 million, which is expected to fund operations at least into the fourth quarter of 2024.

08:04 EDT Cogent Biosciences expects cash to fund operations into 2025 - As of March 31, 2023, cash, cash equivalents and marketable securities were $220.3 million as compared to $259.3 million as of December 31, 2022. Total cash spent was $39.0 million, including a one-time payment of $5.1 million related to performance-based bonus compensation. Based on its current plans, the company expects its existing cash and cash equivalents will be sufficient to fund its operating expenses and capital expenditure requirements into 2025.

07:59 EDT Monarch Mining reports additional results from the McKenzie Break gold project - MONARCH MINING reports additional results from the 2022 drilling program on its wholly-owned McKenzie Break gold project, located 25 kilometres north of the Corporation's wholly owned Beacon mill. The 2022 drilling program on the McKenzie Break property totaled 16,104 metres in 53 holes. Today, Monarch is reporting the results from an additional 13 holes totalling 4,523 metres. Assays are pending for the remaining 17 holes of this drill program. "The known limits of the McKenzie Break mineralization continue to be extended near-surface and at depth as per our geological model, confirming that the proposed pit limits can be expanded," said Jean-Marc Lacoste, President and Chief Executive Officer of Monarch. "We expect the remaining drill assays will continue to give positive results and further expand the known mineralization."

07:58 EDT Adaptive announces FDA acceptance of Genetech's new IND application - Adaptive Biotechnologies announced that the U.S. Food and Drug Administration, FDA, has accepted an investigational new drug, IND, application submitted by its collaborator, Genentech, a member of the Roche Group, for a T-cell receptor, TCR, based T-Cell Therapy. This is the first TCR-based therapeutic product candidate to advance into clinical development based on Adaptive's collaboration with Genentech in oncology. "This IND acceptance reaffirms the value of our immune medicine platform and Adaptive's ability to identify and characterize clinical grade, therapeutic T-cell receptors, which is the cornerstone of our drug discovery capabilities," said Chad Robins, chief executive officer and co-founder, Adaptive Biotechnologies. "We look forward to supporting Genentech's world-class team of scientists and drug developers to advance this potentially life-saving therapy into the clinic for patients with solid tumors." Under the terms of Adaptive and Genentech's collaboration agreement, Genentech has responsibility for clinical, regulatory and commercialization efforts for any T-Cell Therapy product candidate. Adaptive reiterates its full year revenue guidance in the range of $205 to $215 million.

07:56 EDT Aehr Test Systems receives order for FOX-XP system - Aehr Test Systems announced it has received the first order for a new high-power configuration of its FOX-XP system for production wafer level burn-in of next generation silicon photonics integrated circuits from a current major silicon photonics customer. This FOX-XP multi-wafer test and burn-in system is configured to enable cost-effective production test of the next generation of silicon photonics ICs, which can require up to two to four times as much power for full wafer test, burn-in, and stabilization of the silicon photonics devices. Shipment of this new higher-power configured FOX-XP is scheduled for the first quarter of 2024. Gayn Erickson, President and CEO of Aehr Test Systems, commented, "We are excited to receive this first order for this system configuration from one of the world's largest semiconductor manufacturers and expect them to order additional production systems as they ramp capacity for these devices. This new FOX production system configuration expands the market opportunities of the FOX-XP system, as it's able to test, burn-in, and stabilize up to nine 300mm wafers in parallel with up to 3.5 kW of power per wafer, which is beyond the wafer parallelism and power capacity of any system on the market. The system is also configured to allow direct docking to Aehr's new fully automated FOX WaferPak Aligner and material handling system."

07:54 EDT MediWound announces $10M award from BARDA - MediWound announced that the Biomedical Advanced Research and Development Authority, part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services, has awarded an additional $10 million to MediWound. The supplemental funding will support a $3 million replenishment of expired product previously procured for emergency preparedness, the pediatric indication sBLA submission to the U.S. Food and Drug Administration, and enrollment of an additional 50 patients in the ongoing expanded access treatment protocol.

07:52 EDT Evoke Pharma presents data on GIMOTI at DDW 2023 - Evoke Pharma announced the details of its presentation at Digestive Disease Week, DDW, 2023 demonstrating that GIMOTI reduces healthcare resource utilization for patients with diabetic gastroparesis versus patients on oral metoclopramide. Selected by DDW leadership for presentation alongside a total of only six meritorious clinical abstracts from more than 3,500 that were submitted, Dr. David C. Kunkel, Gastroenterologist and Associate Professor of Medicine at UC San Diego Health, delivered the data to the AGA Distinguished Plenary Session. Select data points and key findings from the real-world data analysis are outlined below: Cohorts were selected from patients prescribed NMCP and from within a national database of 100 million patients of those receiving OMCP; these groups were statistically matched using a propensity score with 257 subjects in each category for a total of 514 patients. 77% of patients were female. 31.1% of subjects in both groups experienced an ED visit or inpatient hospitalization during the 6-months prior to index. Patients treated with NCMP had 99 fewer physician office visits, 1 additional outpatient visit, 34 fewer inpatient hospitalizations and 84 fewer ED visits for DGP-related causes in the 6 month follow up period. Patients treated with NMCP had 124 fewer physician office visits, 55 fewer outpatient facility visits, 37 fewer inpatient hospitalizations, and 167 fewer ED visits for any cause in the 6-month follow-up period. Statistically, the likelihood of a patient treated having a DGP related physician office visit was 36% lower in the NMCP cohort. Similarly, for inpatient hospitalizations and emergency department visits the likelihood was 68% and 60% lower, respectively, for NMCP-treated patients versus OMCP. Conclusions: In a matched comparison, NMCP-treated patients had significantly fewer nausea and vomiting or DGP-related office visits, ED visits, and inpatient hospitalizations in the 6 months following start of therapy. The reduction in DGP-related HCRU equated to an avoidance of 99 physician office visits, 84 fewer ED visits, and 34 fewer inpatient hospitalizations for NMCP patients versus OMCP patients in a 6-month period. Overall, the likelihood of a DGP patient treated with NMCP visiting the ED or being admitted to the hospital was less than half that of patients treated with OMCP during the same period

07:51 EDT Wheels Up CEO Kenny Dichter stepping down, CFO Todd Smith named Interim CEO - Wheels Up CEO Kenny Dichter will step away from his role as CEO. Dichter will continue to be a member of the Board of Directors. Current Board member Ravi Thakran - former Group Chairman, Asia for LVMH and former Chairman and Founding Partner, L Catterton Asia - will serve as Executive Chairman, and CFO Todd Smith has been named interim CEO, reporting to Thakran. Wheels Up has retained a leading executive search firm to identify a permanent CEO. Smith joined Wheels Up in 2022 following a 25-year career at General Electric where he worked in a number of senior divisional CFO roles, ultimately serving as Global Head of Financial Planning and Analysis and CFO for GE Corporate. He will continue to serve as the Wheels Up CFO.

07:50 EDT Lithium Ionic reports assay results from Bandeira property - Lithium Ionic reports assay results from its 100%-owned Bandeira property as part of a 30,000-metre drill program at the Itinga Project, located within the lithium-rich Aracuai district in the state of Minas Gerais, Brazil. The results from this campaign will culminate in an initial mineral resource estimate expected this quarter. Bandeira is located approximately 500 metres south of Companhia Brasileira de Litio's Cachoeira lithium mine, and approximately 700 metres north of Sigma Lithium Corp.'s large Barreiro lithium deposit. The Company is currently the second largest mineral rights holder in the region, controlling 14,182 hectares in this emerging hard rock lithium-producing district. Bandeira Drill Intercept Highlights 1.62% Li2O over 20m: Drilled in the northernmost extent of the property, this hole intersected a new high-grade zone of mineralization approximately 104 metres down hole. 1.42% Li2O over 15.8m and 1.73% Li2O over 11m. Intersected 300 metres down-dip from previously reported holes ITDD-23-054 and ITDD-23-058 which intersected 1.84% Li2O over 6.45m and 1.44% Li2O over 6m, respectively. Extension to be confirmed with pending holes ITDD-23-084 and ITDD-23-078. 1.24% Li2O over 18.1m, 1.99% Li2O over 6.7m, 1.66% Li2O over 8m and 2.10% Li2O over 4m. Identified several well-mineralized intersections, the thickest of which is located ~500 metres from surface and 700 metres down-dip from previously reported holes ITDD-22-024 and ITDD-22-025. 2.03% Li2O over 4.3m, 1.44% Li2O over 5.1m and 1.79% Li2O over 2.8m. 1.62% Li2O over 8m. A highlight interval among a group of positive results in the south end of the property, which intersected a shallow mineralized pegmatite zone, discordant to the regional foliation.

07:49 EDT HilleVax announces appointment of Cocero to board of directors - HilleVax (HLVX) announced the appointment of Nanette Cocero, Ph.D., MBA, to its Board of Directors, effective May 8, 2023. Dr. Cocero served as the Global President of Pfizer Vaccines during the last four years and is a recognized leader in global healthcare. Dr. Cocero is a seasoned pharmaceutical executive with over 25 years of experience in diverse leadership positions. Most recently, Dr. Cocero was the Global President of Pfizer Vaccines (PFE).

07:47 EDT Perella Weinberg Partners announces Dunn has joined as a Partner - Perella Weinberg Partners announced that Kempton Dunn has joined the Firm as a Partner in the Advisory Business. Dunn joins PWP with over twenty-five years of investment banking experience, advising corporate, private equity and venture capital clients on strategy, M&A and financing transactions in the enterprise software sector. Prior to joining PWP, Dunn served as a Partner at Centerview Partners.

07:46 EDT Acreage Holdings CFO Steve Goertz resigns - Acreage Holdings announced that Steve Goertz has resigned from his position as CFO effective June 15, 2023. The Company has initiated a search process to fill the role of CFO as it progresses toward completing its previously announced arrangement involving Canopy Growth Corporation. Prior to the conclusion of his role, Mr. Goertz will lead the preparation and filing of the Company's financial statements for the first quarter of 2023 and assist in the transition.

07:44 EDT Plug Power down 12% at $8.20 after Q1 earnings miss, below-consensus guidance

07:40 EDT Seres Therapeutics receives $125M milestone payment from Nestle Health Science - Seres Therapeutics (MCRB) has "substantially strengthened our balance sheet and expect to further enhance our cash position with the receipt of a $125M milestone payment from Nestle (NSRGY) based on the FDA approval."

07:35 EDT Palatin presents PL8177 ulcerative colitis data at DDW conference - Palatin Technologies announced the presentation of the poster "Efficacy of the Melanocortin Receptor Agonist PL8177 as a Potential Therapy for Gastrointestinal Inflammatory Diseases" at the Digestive Disease Week annual meeting May 6-9, 2023 in Chicago, Illinois. The poster was presented by John Dodd, Ph.D., Senior Vice President of Preclinical Research at Palatin. The data shows the high potency of PL8177, and lack of systemic absorption, which makes a delayed-release microparticle oral formulation of the melanocortin-1 receptor agonist PL8177 a promising new candidate for clinical development for the treatment of inflammatory bowel disease. In preclinical studies in rat models of ulcerative colitis, oral PL8177 was found to be efficacious in reducing colonic damage and inflammation. In rats and dogs, data showed that oral PL8177 is released in the lower GI tract where it can exert its effect on inflammation. Clinical data presented in the poster shows that oral PL8177 was released in the GI tract and did not reach systemic circulation. A phase 2 study, PL8177-205, is currently enrolling patients. An interim assessment and topline data is anticipated in the second half of 2023.

07:32 EDT B. Riley Financial acquires certain assets of ABTV, no terms - B. Riley Financial announced that it has acquired certain assets of ABTV, an independent business and financial advisory firm based in Charlotte, North Carolina. Formerly known as Anderson Bauman Tourtellot Vos, ABTV specializes in improving and restoring performance and maximizing value for distressed and underperforming organizations. In connection with the transaction, senior restructuring advisors Edward J. Sanz and P. Michael Kain have joined B. Riley Advisory Services. The former ABTV headquarters in Charlotte, NC will be re-established as a B. Riley office.

07:30 EDT BioCardia announces U.S. patent on bone marrow derived NK1R+ MSCs - BioCardia announces that the United States Patent Office has granted Patent Number 11,642,377: titled, " Bone Marrow Derived Neurokinin-1 Receptor Positive Mesenchymal Stem Cells for Therapeutic Applications", with a patent term that will expire in 2039. The patent specification details methods for selecting and expanding NK1R+ Mesenchymal Stem Cells and their use to treat a number of diseases. The first allowed claim protects using these cells to treat cardiovascular disease, pain, rheumatoid arthritis, diabetes, stroke, asthma, pulmonary fibrosis, and aging. There are seventeen additional claims allowed in this patent issuance.

07:28 EDT Mobilicom receives repeat purchase order from UAE government organization - Mobilicom announced a repeat purchase order for its robust end-to-end solutions from by a leading UAE government organization. The customer purchased Mobilicom's entire product offering, including hardware and software, demonstrating the effectiveness of Company's end-to-end solutions strategy for uncrewed and autonomous systems.

07:27 EDT Galmed initiates program to evaluate Primary Sclerosing Cholangitis - Galmed initiated a new clinical program to evaluate its lead compound, Aramchol meglumine for the Treatment of Primary Sclerosing Cholangitis. PSC is a chronic cholestatic liver disease, characterized by progressive and multifocal fibrosis of the biliary system, which typically results in cirrhosis and fibrotic liver disease. It is a rare disease with no approved treatment that qualifies for the status of an orphan disease in the U.S. and E.U.; it is estimated that ~70% of the PSC patients have underlying IBD, most frequently ulcerative colitis. Galmed plans to initiate a Phase 2 study in the last quarter of 2023. The clinical trial will evaluate the effects of 24 weeks of treatment with Aramchol meglumine in approximately 15 patients with PSC. The study's endpoints will include the conventional relevant laboratory parameters, histological fibrosis and molecular assessment as well as a range of biomarkers of disease activity and fibrosis.

07:26 EDT HCW Biologics expects cash to fund operations into 2025 - As disclosed above, the Company entered into a development line of credit agreement for the buildout of the Company's new headquarters and manufacturing facility. Funds formerly earmarked for this purpose will be redeployed for clinical development. The Company estimates that the cash and cash equivalents, short-term investments and the proceeds of the development line of credit extends the Company's cash runway into 2025.

07:24 EDT ViaSat acquisition of Inmarsat receives CMA clearance - Viasat announced that the UK's Competition & Markets Authority, or CMA, has announced the conclusion of its Phase II review, which confirmed its provisional findings that the transaction does not raise competition concerns, and allows Viasat's proposed acquisition of Inmarsat to proceed without remedies. This decision is an important milestone towards completion of the deal. The proposed transaction has now received clearance from the UK government under the National Security and Investment Act and the CMA, as well as the Australian government's Foreign Investment Review Board, or FIRB, and the Committee on Foreign Investment in the United States.

07:24 EDT Wingstop reaches 2,000th restaurant milestone - Wingstop announced the opening of its 2,000th global restaurant in Pittsburgh, PA. This milestone comes on the heels of continued, industry-leading momentum, having delivered 20% same-store sales growth in the first quarter of 2023 and achieving its 19th consecutive year of same-store sales growth in 2022. With significant whitespace ahead, this development milestone is one step in Wingstop's journey to Top 10 Global Restaurant Brand status, with a goal of over 7,000 restaurants globally.

07:21 EDT Timken investing $70M to expand wind energy solution capacity - Timken announced a new $70M investment to further expand manufacturing capabilities to support increased demand for its wind energy solutions. This adds to its previously announced $75M commitment to strengthen both wind and solar capabilities, bringing the total investment to $145M since 2020 to expand the company's renewable energy capacity in Europe and Asia. The additional $70 million investment includes automated manufacturing equipment and will result in increased production capacity of engineered bearings for wind turbines. Renewable energy is Timken's single-largest end-market sector, representing more than 10% of the company's total sales in 2022.

07:13 EDT Esperion sees 2023 operating expenses $225M-$245M - The Company still expects full year 2023 operating expenses to be approximately $225 million to $245 million, including $25 million in non-cash expenses related to stock compensation.

07:02 EDT Acumen expects cash to fund operations through 2025 - As of March 31, 2023, cash, cash equivalents and marketable securities totaled $183.8 million, compared to cash, cash equivalents and marketable securities of $193.4 million as of December 31, 2022. The decrease in cash is related to funding ongoing operations.

06:55 EDT Synlogic granted FDA orphan drug designation for SYNB1934 - Synlogic announced that the U.S. FDA has granted orphan drug designation to SYNB1934 for the treatment of phenylketonuria.

06:46 EDT Nintendo reports 2023 hardware units sold 17.97M, down 22.1% y-o-y - The company said, "Looking at the Nintendo Switch business for the full fiscal year, good sales were posted for Pokemon Scarlet and Pokemon Violet, which recorded a total sales of 22.10 million units, and for Splatoon 3, which sold 10.67 million units. Other new titles released during the period also performed well, with Nintendo Switch Sports selling 9.60 million units. Among titles released through the end of the previous fiscal year, Mario Kart 8 Deluxe sold 8.45 million units, and Kirby and the Forgotten Land sold 3.81 million units. As a result, there were 35 titles that sold over a million copies during the period, including titles from other software publishers. As for hardware, units sold declined 22.1% year-on-year to 17.97 million units, as shortages of semiconductors and other components impacted production until around the end of summer, and we did not experience the growth in sales mainly during the holiday season that we saw in the previous fiscal year. The sales situation for software remained stable, but unit sales declined 9.0% year-on-year to 213.96 million units, affected to some extent by the decline in hardware sales. Turning to the digital business for our dedicated video game platform, in addition to the impact of the depreciation of yen, sales of the downloadable versions of packaged software for Nintendo Switch performed well, and revenue related to Nintendo Switch Online increased, helping to push digital sales to 405.2 billion yen, up 12.7% year-on-year."

06:43 EDT AstraZeneca says Farxiga extended in U.S. to reduce risk of cardiovascular death - AstraZeneca's Farxiga has been approved in the U.S. to reduce the risk of cardiovascular death, hospitalization for heart failure and urgent heart failure visits in adults with HF, the company announced. The approval by the Food and Drug Administration was based on positive results from the DELIVER Phase III trial. Farxiga was previously approved in the US for adults with HF with reduced ejection fraction, or HFrEF.

06:38 EDT Tempur Sealy to acquire Mattress Firm for $4B in cash, stock

06:24 EDT Swvl receives delayed listing notice from Nasdaq - Swvl Holdings received written notice from Nasdaq on May 4 indicating that, as a result of not having timely filed its Annual Report for 2022, the company is not in compliance with Nasdaq Listing Rules. Nasdaq requires that the company submit a plan no later than July 3, to regain compliance. If Nasdaq accepts the plan, Nasdaq can grant the company an extension of up to 180 calendar days from the due date of the Form 20-F to regain compliance. The Notice has no immediate impact on the listing of the company's securities, which will continue to trade on Nasdaq, subject to the company's compliance with other continued listing requirements of Nasdaq.

06:17 EDT Standard Lithium signs JDA with Koch Technology Solutions - Standard Lithium is pleased to announce that it has signed a Joint Development Agreement with Koch Technology Solutions, an affiliate of Koch Engineered Solutions, to share data and jointly develop and commercialize integrated lithium brine processing flowsheets for Standard Lithium's exclusive use in the Smackover Formation. The agreement will further enhance Standard Lithium's position to build the first U.S. commercial lithium project in several decades and to begin to meet the surging demand for lithium. Under the JDA, Standard Lithium and KTS will work together to integrate the proprietary KTS Li-Pro Lithium Selective Sorption technology into a complete flowsheet solution, and Standard Lithium will have exclusive rights to deploy this technology at any of its projects in the Smackover Formation under a license agreement. KTS will also provide firm performance guarantees for the deployment and operation of the technology at high levels of commercial lithium extraction, allowing Standard Lithium to accelerate the development process cost-efficiently.

06:14 EDT Trivago says Johannes Thomas assumes role of CEO, succeeding Axel Hefer - Trivago announced a signicant transformation in its leadership structure, welcoming a team of accomplished travel industry executives, who played signicant roles in the company's worldwide growth. Effective May 9, Johannes Thomas assumes the role of CEO and Managing Director, succeeding Axel Hefer, who has chosen not to extend his contract. With a rich background in the travel sector and deep familiarity with trivago, Thomas brings invaluable expertise to his new role. Having started as an intern during trivago's early days, he rose through the ranks to become Managing Director and Chief Revenue Officer until 2020. Thomas pioneered trivago's performance marketing teams and revolutionized the way the company connects advertisers with its vast traveler base. He also led the Business Operations and Strategy Department, spearheading key strategic initiatives. Joining Thomas in the new leadership team are former trivago executives Jasmine Ezz as Chief Marketing Officer and Andrej Lehnert as Chief Product Officer. Ezz played a critical role in scaling trivago's brand presence and served as Global Head of Media Buying. Lehnert previously held positions as both Chief Product Officer and Chief Marketing Officer at trivago. This dynamic team brings a wealth of marketing, product, and operational expertise to the table, with the aim of unlocking significant value and driving a sustainable positive trajectory for the company. The team will be complemented by Matthias Tillmann who will continue in his role as trivago CFO.

05:50 EDT UBS: Todd Tuckner to succeed Sarah Youngwood as CFO at deal close

05:44 EDT Genentech announces FDA acceptance of Vabysmo sBLA - Genentech, a member of Roche, announced that the FDA has accepted the company's supplemental Biologics License Application, or sBLA, for Vabysmo for the treatment of macular edema following retinal vein occlusion, or RVO. The sBLA is based on results from the Phase III BALATON and COMINO studies that demonstrated treatment with Vabysmo provided early and sustained improvement in vision, meeting the primary endpoint of non-inferior visual acuity gains at 24 weeks compared to aflibercept. Vabysmo's safety profile was consistent with previous trials.

05:39 EDT Iveco Group, Nikola enter new phase of partnership - Iveco Group (IVCGF) and Nikola (NKLA) announced that they are entering a new phase of their partnership, which started in 2019 and has so far met all milestones to leverage the respective expertise to deploy zero-emission heavy-duty trucks in North America and Europe. The two companies worked jointly to achieve the outcomes of the previous phase, launching Battery Electric Vehicles, or BEV, and Fuel Cell Electric Vehicles, or FCEV, for regional and long haulage. Iveco Group will concentrate on Europe for the further development and commercialization of its own battery electric and fuel cell electric trucks, which includes rolling out its financing business model GATE, and Nikola will focus its operations in North America, with an integrated approach to its customers, offering BEV, FCEV and hydrogen infrastructure via its HYLA brand. Iveco Group will assume full ownership of the joint venture in Ulm, Germany. Also, Iveco Group will be licensed to freely access and continue developing vehicle control software for the jointly developed BEV and FCEV. Nikola will be granted the IVECO S-Way technology license for North America and related component supply from Iveco Group, and will gain joint ownership of the intellectual property of Generation 1 eAxles, technology developed together with Iveco Group's powertrain brand, FPT Industrial. Iveco Group will cover the capital outlay related to this new phase of collaboration through its available liquidity, acquiring the above-named items partially in cash, $35M, and partially in Nikola shares, 20M shares. Despite the negative cash impact generated, Iveco Group forecasts to absorb it with cash flow generation and therefore this does not change its cash flow target for 2023; it will also retain Nikola shares. Iveco Group and Nikola will continue to work towards the same ultimate goal: to lead the energy transition to the future of mobility. The above-mentioned provisions are subject to all applicable regulatory approvals and preparation of definitive agreements to more fully implement the terms of the binding terms sheet between the companies.

05:22 EDT Li-Cycle, Glencore sign LOI to jointly develop recycling hub in Italy - Li-Cycle (LICY) and Glencore International AG, a wholly-owned subsidiary of Glencore (GLNCY), have signed a letter of intent to jointly study the feasibility of, and later, develop a Hub facility in Portovesme, Italy. The Portovesme Hub would produce critical battery materials, including nickel, cobalt and lithium from recycled battery content. Located in Sardinia, Italy, the Portovesme metallurgical complex consists of a lead-zinc smelter and hydrometallurgical facility which first started operations in 1929. The Portovesme site has substantial existing infrastructure, including access to a port, utilities, processing equipment from the hydrometallurgical plant and an experienced workforce. Li-Cycle and Glencore will jointly commence a definitive feasibility study, or DFS for this project within 60 days from this announcement. The DFS is expected to be completed by mid-2024. Subject to a final investment decision by the parties, the project will proceed to construction with commissioning of the Portovesme Hub expected to commence in late 2026 to early 2027. Li-Cycle and Glencore also anticipate forming a 50/50 joint venture that would repurpose part of the existing Glencore metallurgical complex in Portovesme, Italy to create the Portovesme Hub. This would enable a development plan. The project also contemplates long-term financing from Glencore to fund Li-Cycle's share of the capital investment. Once operational, the Portovesme Hub is expected to have processing capacity of up to 50,000 to 70,000 tons of black mass annually, or the equivalent of up to 36 GWh of lithium-ion batteries. The black mass processed at the Portovesme Hub is expected to be supplied from Li-Cycle's growing Spoke network in Europe and through Glencore's commercial network. The Portovesme Hub is expected to be the first facility of its kind and scale to come online in Europe. Together with Li-Cycle's Spoke network, and Glencore's battery circularity platform, this facility would enable Europe to get one step closer to closing the loop on manufacturing scrap, as well as end-of-life batteries, fully within Europe, using hydrometallurgical processes.

05:12 EDT Elbit Systems awarded $71M contract by UK Ministry of Defence - Elbit Systems announced that its UK subsidiary Elbit Systems UK was awarded a contract from the UK Ministry of Defence worth approximately $71M to supply, maintain and operate the Ground Manoeuvre Synthetic Trainer systems, or GMST, for the Boxer armoured vehicles and Challenger 3 tanks under the British Army's Project Vulcan. The contract will be delivered over a three-year period with an additional nine year period that will include operation and maintenance services at UK facilities.

05:07 EDT DouYu reponds to regulatory review - DouYu announced that the Hubei provincial branch of the Cyberspace Administration of China, or the CAC, has sent an inspection team to the company due to certain alleged violations of content rules and regulations on its platform. The CAC team is expected to conduct a one-month on-site inspection of the company's content platform, which DouYu will fully cooperate with. DouYu is also concurrently conducting a comprehensive internal review of its content monitoring system. As a platform committed to regulatory compliance and the safety of its user community, DouYu plans to implement all necessary remedial measures based on the CAC inspection and its own internal review. DouYu is expected to maintain its normal operations during this period of time.